Home・Aandelen Lijst・Glaukos Corp

Glaukos Corp

Gesloten

SectorGezondheidszorg

184.26 0.69

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

177.92

Max

183.72

Belangrijke statistieken
By Trading Economics
Inkomsten	1.4M -18M
Verkoop	35M 186M
EPS	-0.14
Winstmarge	-9.901
Werknemers	1,094
EBITDA	-11M -16M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+3.03% upside

Dividenden
By Acuity
Volgende Winsten	28 okt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.8B 11B
Vorige openingsprijs	183.57
Vorige sluitingsprijs	184.26

Nieuwssentiment

By Acuity

34%

66%

79 / 340 Rangschikking in Healthcare

Glaukos Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 aug 2026, 20:06 UTC

Glaukos Corp shares are higher today, following a broader market trend since Friday. Earlier, the stock reached a session high before pulling back.

7 aug 2026, 20:02 UTC

Glaukos Corp shares are rising in Friday's session, supported by unusually high trading volume and a steady upward trend since Thursday's close.

4 aug 2026, 19:36 UTC

Glaukos Corp shares are lower today, impacted by declines in the Health Care Equipment sub-sector. The stock pulled back after reaching an earlier high.

3 aug 2026, 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31 jul 2026, 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30 jul 2026, 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29 jul 2026, 21:22 UTC

Social Media

News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28 jul 2026, 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27 jul 2026, 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24 jul 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21 jul 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Peer Vergelijking

Prijswijziging

Glaukos Corp Prognose

Koersdoel

By TipRanks

3.03% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 186.92 USD 3.03%

Hoogste 215 USD

Laagste 153 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Glaukos Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Gebaseerd op 14 analisten die aandelenratings hebben gegeven aan Glaukos Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

79 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.